Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To determine the antiviral activity, pharmacokinetics, pharmacodynamics, safety, and tolerability of several dose levels of oral TBR-652 monotherapy in HIV-1-infected, antiretroviral experienced, CCR5 antagonist-naive subjects. DESIGN: Double-blind placebo-controlled study in the United States and Argentina. METHODS: Subjects were randomized in a ratio of 4:1 per dose level to TBR-652 (25, 50, 75, 100, or 150 mg) or placebo, taken once daily for 10 days. Changes from baseline in HIV-1 RNA and CD4 cell counts were measured through day 40 and for monocyte chemotactic protein-1 (MCP-1), high-sensitivity C-reactive protein (hs-CRP), and IL-6 at day 10. Pharmacokinetic data were analyzed using noncompartmental statistics. Laboratory and clinical adverse events (AEs) and electrocardiogram changes were recorded. RESULTS: Maximum median reductions in HIV-1 RNA values for the 25, 50, 75, and 150 mg doses were -0.7, -1.6, -1.8, and -1.7 log10 copies per milliliter, respectively. All changes were significant. Median time to nadir was 10-11 days. Suppression persisted well into the posttreatment period. Mean MCP-1 increased significantly by day 10 in the 50-mg and 150-mg dose groups. Effects on CD4 cell counts, hs-CRP, and IL-6 levels were negligible. TBR-652 was generally safe and well tolerated, with no withdrawals due to AEs. CONCLUSIONS: TBR-652 caused significant reductions in HIV-1 RNA at all doses. Significant increases in MCP-1 levels suggested a strong CCR2 blockade. TBR-652 was generally well tolerated with no dose-limiting AEs. Pharmacodynamics indicate that TBR-652 warrants further investigation as an unboosted once-daily oral CCR5 antagonist with potentially important CCR2-mediated anti-inflammatory effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.
Kuller, L. H., Tracy, R., Belloso, W., Wit, S. D., Drummond, F., Lane, H. C., Ledergerber, B., Lundgren, J., Neuhaus, J., Nixon, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050203 · Cited by 1,617
Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection
Neuhaus, J., Jacobs, Jr., Baker, J. V., Calmy, A., Duprez, D., La Rosa, A., Kuller, L. H., Pett, S. L., Ristola, M., Ross, M. J., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/652749 · Cited by 869 · cited 8×
“General disorders and administration site conditions 0 2 (22) 0 0 1 (10) 5 (56)”
BackgroundInfluential
Cited by
Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007724 · Cited by 850
Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Ratziu, V., Sanyal, A., Harrison, S. A., Wong, V. W., Francque, S., Goodman, Z., Aithal, G. P., Kowdley, K. V., Seyedkazemi, S., Fischer, L., et al. (2020) · Hepatology · doi:10.1002/hep.31108 · Cited by 378
Mossanen, J. C., Krenkel, O., Ergen, C., Govaere, O., Liepelt, A., Puengel, T., Heymann, F., Kalthoff, S., Lefebvre, E., Eulberg, D., et al. (2016) · Hepatology · doi:10.1002/hep.28682 · Cited by 325
Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158156 · Cited by 323
“In addition, CVC exhibited a good tolerability profile in humans, including hepatically impaired subjects [21,25,26].”
BackgroundSelf-citation
Metadata
- Authors
- Lalezari, J., Gathe, J., Brinson, C., Thompson, M., Cohen, C., Dejesus, E., Galindez, J., Ernst, J. A., Martin, D. E., & Palleja, S. M.
- Venue
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2011-06-01
- Volume
- 57
- Issue
- 2
- Pages
- 118-125
- ISSN
- 1525-4135 (ISSN-L)
- OpenAlex
- W2069953817
- Cited by
- 64
- References
- 2
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects. https://app.cochat.ai/papers/10.1097/qai.0b013e318213c2c0
- The paper
- Lalezari, J., Gathe, J., Brinson, C., Thompson, M., Cohen, C., Dejesus, E., Galindez, J., Ernst, J. A., Martin, D. E., & Palleja, S. M. (2011). Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/qai.0b013e318213c2c0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.